Quarterly ResultAug 10, 2026, 04:20 PM
Nkarta Q2 Net Loss $40.4M; Cash $243.2M, Funds Ops into 2029
AI Summary
Nkarta, Inc. reported a net loss of $40.4 million, or $0.54 per share, for the second quarter ended June 30, 2026. The company maintained a cash balance of $243.2 million, which is projected to fund operations into 2029. Nkarta also provided updates on its NKX019 clinical program, including continued patient enrollment in Ntrust-1 and Ntrust-2 trials for autoimmune diseases, the initiation of outpatient dosing, and the expectation to present initial clinical data at a medical conference in 2026.
Key Highlights
- Net loss was $40.4 million for the second quarter ended June 30, 2026.
- Net loss per share was $0.54 for the second quarter of 2026.
- Cash, cash equivalents, and investments totaled $243.2 million as of June 30, 2026.
- Current cash and cash equivalents are expected to fund operations into 2029.
- Research and development expenses were $29.0 million for Q2 2026.
- General and administrative expenses were $14.1 million for Q2 2026.
- Enrollment continues across all indications in Ntrust-1 and Ntrust-2 clinical trials.
- Initial clinical data from Ntrust-1 and Ntrust-2 are expected in 2026.
Price Impact
More from NKTX